Galapagos Genomics NV And Oneworld Health Collaborate To Develop New Drugs For The Treatment Of Diarrheal Diseases

MECHELEN, BELGIUM -- (MARKET WIRE) -- September 06, 2006 -- Mechelen, Belgium and San Francisco, California, USA; 6 September 2006 - Galapagos NV (Euronext & LSE: GLPG) announced today that its service division BioFocus DPI has entered into a drug discovery collaboration with the Institute for OneWorld Health, a non-profit pharmaceutical company headquartered in San Francisco, California. OneWorld Health is working on a number of drug development initiatives for neglected diseases, with support from the Bill & Melinda Gates Foundation and other donors. The collaboration focuses on the development of new drugs to combat diarrheal diseases, a fundamental threat to the health of children in the developing world. Under the terms of the agreement, BioFocus DPI will apply its medicinal chemistry expertise to identify new drug candidates for OneWorld Health's diarrheal disease program. Total contract value for Galapagos exceeds EUR 3 million over two and a half years.

Back to news